Table 2.
The relationship between serum sIL-2R and TSGF level and clinicopathological parameters in patients with PTC.
| sIL-2R | TSGF | |||||||
|---|---|---|---|---|---|---|---|---|
| Low | High | χ 2 | P | Low | High | χ 2 | P | |
| Gender | ||||||||
| Male | 18 (45.0) | 22 (55.0) | 4.464 | 0.035∗ | 20 (50.0) | 20 (50.0) | 0.301 | 0.583 |
| Female | 105 (63.6) | 61 (36.4) | 91 (54.8) | 75 (45.2) | ||||
| Age | ||||||||
| ≤45 years | 65 (63.1) | 38 (36.9) | 0.989 | 0.32 | 54 (52.4) | 49 (47.6) | 0.176 | 0.675 |
| >45 years | 58 (56.3) | 45 (43.7) | 57 (55.3) | 46 (45.7) | ||||
| Tumor size | ||||||||
| ≤1 cm | 99 (61.1) | 63 (38.9) | 0.62 | 0.431 | 89 (54.9) | 73 (45.1) | 0.34 | 0.56 |
| >1 cm | 24 (54.5) | 20 (45.5) | 22 (50.0) | 22 (50.0) | ||||
| Nodular goiter | ||||||||
| No | 47 (63.5) | 27 (37.5) | 0.695 | 0.404 | 39 (52.7) | 35 (47.3) | 0.065 | 0.799 |
| Yes | 76 (57.6) | 56 (42.4) | 72 (54.5) | 60 (45.5) | ||||
| HT | ||||||||
| No | 100 (60.2) | 66 (39.8) | 0.101 | 0.751 | 91 (54.8) | 75 (45.2) | 0.301 | 0.583 |
| Yes | 23 (57.5) | 17 (42.5) | 20 (50.0) | 20 (50.0) | ||||
| Focality | ||||||||
| Unifocality | 76 (63.9) | 43 (36.1) | 2.024 | 0.155 | 72 (60.5) | 47 (39.5) | 4.97 | 0.026∗ |
| Multifocality | 47 (54.0) | 40 (46.0) | 39 (44.8) | 48 (55.2) | ||||
| Capsular invasion | ||||||||
| No | 86 (63.2) | 50 (36.8) | 2.069 | 0.15 | 72 (52.9) | 64 (47.1) | 0.143 | 0.705 |
| Yes | 37 (52.9) | 33 (47.1) | 39 (55.7) | 31 (44.3) | ||||
| LNM | ||||||||
| No | 71 (56.3) | 55 (43.7) | 1.522 | 0.217 | 75 (59.5) | 51 (40.5) | 4.154 | 0.042∗ |
| Yes | 52 (65.0) | 28 (35.0) | 36 (45.0) | 44 (55.0) | ||||
∗ P < 0.05.